Prostatype Genomics AB is a Sweden-based company developing gene tests. The Company's business model and concept is to manufacture, market and sell the Prostatype Test System as one prognostic package consisting of the Prostatype RTqPCR kit, the patient database and the evaluation software and accessories P-score. The test is supposed to check the aggressiveness of the prostate cancer in order to help clinicians and patients to make correct treatment decisions. Prostatype analyzes the gene expression in cancer cells extracted from prostate tissue and gives, in combination with an advanced algorithm and data analysis, decision support for optimal treatment of individual patients once prostate cancer has been confirmed.

Employees

Sector

Healthcare Facilities & Services

More about the company

Income Statement and Estimates

More financial data

Market Closed - OTC Markets Other stock markets 10:40:22 2026-03-25 EDT			5-day change	1st Jan Change
0.1342 ^USD	+57.88%		-.--%	-62.56%

06-30	Prostatype Genomics Board Resolves SEK47 Million Rights Issue	MT
05-31	Prostatype Genomics AB Auditor Raises 'Going Concern' Doubt	CI

Market Cap	10.83M 1.12M 983K 908K 839K 1.58M 108M 1.61M 4.25M 52.88M 4.22M 4.13M 182M	P/E 2024	-0.38x	P/E 2025	-0.23x
Enterprise Value	7.06M 733K 641K 592K 547K 1.03M 70.43M 1.05M 2.77M 34.49M 2.75M 2.69M 119M	EV / Sales 2024	33.9x	EV / Sales 2025	23.6x
Free-Float	27.07%	Yield 2024 *	-	Yield 2025	-

06-30	Prostatype Genomics Board Resolves SEK47 Million Rights Issue	MT
05-31	Prostatype Genomics AB Auditor Raises 'Going Concern' Doubt	CI
05-25	Prostatype Genomics Updates on Medicare Reimbursement Process for Prostatype in United States	CI
05-20	Prostatype Genomics Plans SEK47 Million Rights Issue of Shares, Warrants	MT
05-20	Prostatype Genomics intends to resolve on rights issue	RE
03-04	Prostatype Genomics Expects U.S. Sales to Accelerate in 2026, Says CEO	FW
02-26	Prostatype Genomics reports H2 EBITDA of SEK -17.8 mln	RE
02-26	Prostatype Genomics AB Reports Earnings Results for the Full Year Ended December 31, 2025	CI
01-12	Prostatype Genomics Secures Short-Term Loans of 10 Million SEK	FW
01-12	Prostatype Genomics signs loan financing of SEK 10 million	RE
01-09	Prostatype Genomics Has U.S. Study Published in Medical Journal	FW
01-08	Prostatype Genomics U.S. Validation Study by Veterans Affairs (Va) Is Published	CI
11-11	Prostatype Genomics Unveils Clinically Validated New Product	FW

25-08-04	Analysguiden Holds Off on Valuation of Prostatype, Awaits Regulatory Decision in the US	FW
25-06-12	Analysguiden still sees a good chance that Prostatype Genomics will receive a positive Medicare decision.	FW
24-12-06	Analysis Guide: Prostatype Genomics awaits decisive decision - mission analysis	FW
24-08-28	The analysis guide intends to lower the motivated value for Prostatype Genomics, awaits the outcome of the rights issue	FW
24-05-27	The analysis guide sets a motivated value of SEK 0.12 for Prostatype Genomics	FW

Prostatype Genomics AB Stock OTC Markets

Stocks

PGABF

SE0023261532

Healthcare Facilities & Services

Valuation: Prostatype Genomics AB

Chart: Prostatype Genomics AB

Latest news : Prostatype Genomics AB

Analysts' recommendations: Prostatype Genomics AB

Press Releases: Prostatype Genomics AB

Quotes and Performance

Course Extremes

Managers and Directors: Prostatype Genomics AB

Medical & Diagnostic Laboratories

Financials

Company Profile

Income Statement and Estimates

07-09	The subscription period in Prostatype Genomics AB's rights issue of units begins today	AQ
07-08	Prostatype Genomics AB publishes information memorandum prior to rights issue of units	AQ
07-08	Prostatype Genomics AB enters into top-down underwriting ahead of upcoming rights issue of units	AQ
06-30	Prostatype Genomics : provides financing update	PU
06-29	The Board of Directors of Prostatype Genomics AB resolves on the previously announced rights issue of units of approximately SEK 47.4 million	AQ

Current year	0.08	0.13
1 year	0.08	0.13
3 years	0.08	0.4
5 years	0.08	0.4
10 years	0.08	0.4

Manager	Title	Age	Since
Fredrik Persson CEO	Chief Executive Officer	-	2016-12-31
Lars Anders Koch DFI	Director of Finance/CFO	-	2023-10-30
Katarina Sjoberg LAW	General Counsel	-	2023-02-28

Director	Title	Age	Since
Anders Lundberg CHM	Chairman	-	2016-12-31
Michael Häggman BRD	Director/Board Member	-	2017-12-31
Bengt Håkan Englund BRD	Director/Board Member	74	2018-12-31

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
PROSTATYPE GENOMICS AB	+57.88%	-.--%	-	-	1.44M
NATERA, INC.	-0.08%	-3.06%	+72.37%	+450.16%	39.08B
LABCORP HOLDINGS INC.	-0.36%	-2.88%	+10.36%	+29.57%	22.69B
SONIC HEALTHCARE LIMITED	+2.29%	-0.60%	-21.34%	-39.14%	7.17B
RADNET, INC.	-0.84%	-7.45%	+10.94%	+101.15%	4.98B
DR. LAL PATHLABS LIMITED	+1.13%	+3.48%	+19.23%	+48.15%	3.01B
GENEDX HOLDINGS CORP.	-2.22%	-4.57%	-24.23%	+829.02%	1.9B
DIAN DIAGNOSTICS GROUP CO.,LTD.	-1.78%	+2.27%	+31.09%	-22.51%	1.82B
NEOGENOMICS, INC.	+0.85%	-1.86%	+98.19%	-17.56%	1.84B
FLEURY S.A.	+6.56%	+5.39%	+27.60%	+7.18%	1.71B
Average	+6.34%	-2.23%	+24.91%	+154.00%	9.36B
Weighted average by Cap.	+0.12%	-3.27%	+38.73%	+239.21%

	2024	2025
Net sales	1.92M 199K 174K 161K 149K 280K 19.12M 285K 753K 9.36M 748K 731K 32.24M	594K 61.66K 53.88K 49.81K 46.02K 86.66K 5.92M 88.23K 233K 2.9M 232K 226K 9.99M
Net income	-41.05M -4.26M -3.72M -3.44M -3.18M -5.99M -409M -6.1M -16.11M -200M -16.01M -15.65M -690M	-44.5M -4.62M -4.04M -3.73M -3.45M -6.49M -444M -6.61M -17.46M -217M -17.35M -16.97M -748M
Net Debt	-9.35M -971K -848K -784K -725K -1.36M -93.25M -1.39M -3.67M -45.66M -3.65M -3.57M -157M	-3.77M -391K -342K -316K -292K -550K -37.57M -560K -1.48M -18.4M -1.47M -1.44M -63.34M